Hello. Sign In
Standards Store

CLSI VET02

Revision A3, February 1, 2008

Complete Document

Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline



Detail Summary

Active, Most Current

EN
Additional Comments:
THIRD EDITION; VOL 28; NO 7
Format
Details
Price (USD)
PDF
Single User
$140.00
Print
In Stock
$147.00
Add to Cart

People Also Bought These:

CLSI M07,M100
CLSI M45
CLSI VET04
CLSI M11

Product Details:


Description / Abstract:

This document offers guidance for the development of quality control (QC) limits and interpretive criteria for antimicrobial susceptibility testing (AST), performed by disk diffusion and dilution testing with bacteria isolated from animals, for subcommittee review and, upon approval, inclusion in CLSI document M31.1

The guidance in this document applies to therapeutic antimicrobial agents intended for the treatment or control of systemic or organ-specific infectious disease processes in domestic animals (terrestrial or aquatic). Antimicrobial agents used for growth promotion or prophylaxis (disease prevention) are not included in this document. (See the discussion in CLSI document M311 for more details regarding this issue.) However, the testing methodology described for the development of QC standards may be applicable for those antimicrobial agents that are tested for epidemiological survey or other purposes for which a validated test is required. The subcommittee recognizes that antimicrobial agents are used to treat a variety of enteric infections in animals; thus, a concerted attempt to include them within CLSI document M311 should be made to guide practitioners in the proper selection of agents. NOTE: The guidelines do not apply to directly applied topical antimicrobials such as lotions, cream, ointments, or eye drops.

Since not all antimicrobial agents have veterinary-specific breakpoints or interpretive criteria, the subcommittee has imported breakpoints and zone diameters from CLSI document M1005 (ie, human treatments) into Table 1, Group B of CLSI document M31,1 and designated them by gray shaded listing. Since these breakpoints and interpretive criteria have been developed for human treatment applications, there is uncertainty as to how they apply to specific animal species and disease treatments. To facilitate moving CLSI document M1005 interpretive criteria to veterinary-specific approved status, the Working Group on Generics will provide a gatekeeper function to ensure that presentations to the full subcommittee conform as much as possible to VET02 requirements. This will allow for a consistent approach to address those situations where veterinary-specific data are not readily available within the public domain or where sponsors (ie, manufacturers) are not able or willing to provide data on their products.

Additionally, should there be a need to reevaluate previously established breakpoints or interpretive criteria, a process is outlined in Section 3.6.